Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 318 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... April 24, 2019 Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 Vaping Pods Produce High Nicotine Levels in Young Users October 5, 2018 Aiming to Support Cancer Research, ESMO Calls on the European Council... August 28, 2026 Load more HOT NEWS Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal... New on NCI’s Websites for April 2024 Your Microbiome and Cancer: What to Know Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and...
